Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX in metastatic nasopharyngeal carcinoma
NCT00363831Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Jul 2006
- Primary completion
- Dec 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine and oxaliplatin in nasopharyngeal carcinoma (NPC), sponsored by The University of Hong Kong. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00363831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363831.